Department of General Surgery, Medical School, Baskent University, Ankara, Turkey.
Department of General Surgery, Medical School, Hitit University, Corum, Turkey.
J Coll Physicians Surg Pak. 2021 Jun;31(6):633-637. doi: 10.29271/jcpsp.2021.06.633.
To evaluate the risk factors for developing rectus sheath hematoma (RSH).
An observational study.
Department of General Surgery, Hitit University School of Medicine, Erol Olcok Training and Research Hospital, Turkey; from January 2018 to April 2020.
Patients with RSH were studied. Those with other pathologies in rectus sheath, and repeat studies, were excluded. Demographic data, presenting symptoms, comorbidities, medications administered containing anticoagulant drugs, imaging results, laboratory findings, coagulation parameters, length of hospital stay, treatments administered, type of RSH, morbidity, mortality and risk factors of increased bleeding diathesis, were recorded.
Of the 61 studied patients, 56 (91.8%) had at least one chronic disease, and 77% were receiving anticoagulation therapy. RSH size was significantly larger for patients taking acetylsalicylic acid than for patients taking other anticoagulants, and an RSH area less than 1,924 mm2 was associated with increased length of hospital stay. Binary logistic regression analysis showed that a unit increase in gender was associated with a 1.5-fold increase in the risk of greater RSH size, and that female gender was associated with a 45.3-fold risk of increase in the risk of RSH. Notably, if up to 4 units of erythrocyte suspension replacement is not applied for conservative treatment of RSH, RSH size may increase by 23.5 times.
Risk factors of RSH include chronic obstructive pulmonary disease, congestive heart failure, coronary artery disease, atrial fibrillation, asthma, hypertension, diabetes mellitus, chronic renal failure, prior abdominal surgery, female sex, older age, anticoagulant drug use and cancer-related immunosuppression. Key Words: Rectus sheath hematoma, Conservative treatment, Anticoagulant treatment.
评估发生腹直肌鞘血肿(RSH)的风险因素。
观察性研究。
土耳其厄罗尔·奥尔科克培训与研究医院,埃尔津詹哈提特大学医学院普通外科;2018 年 1 月至 2020 年 4 月。
研究了 RSH 患者。排除了存在腹直肌鞘其他病变和重复研究的患者。记录了人口统计学数据、临床表现、合并症、使用含有抗凝药物的药物、影像学结果、实验室检查结果、凝血参数、住院时间、治疗方法、RSH 类型、发病率、死亡率以及增加出血倾向的风险因素。
在 61 名研究患者中,56 名(91.8%)至少患有一种慢性疾病,77%的患者正在接受抗凝治疗。与服用其他抗凝剂的患者相比,服用乙酰水杨酸的患者 RSH 更大,面积小于 1924mm2 与住院时间延长相关。二项逻辑回归分析显示,性别每增加一个单位,RSH 更大的风险增加 1.5 倍,女性性别与 RSH 风险增加 45.3 倍相关。值得注意的是,如果不对 RSH 进行保守治疗应用多达 4 单位的红细胞悬液替代,RSH 的大小可能会增加 23.5 倍。
RSH 的风险因素包括慢性阻塞性肺疾病、充血性心力衰竭、冠状动脉疾病、心房颤动、哮喘、高血压、糖尿病、慢性肾衰竭、既往腹部手术、女性、年龄较大、使用抗凝药物和癌症相关免疫抑制。关键词:腹直肌鞘血肿,保守治疗,抗凝治疗。